Quinupristin + Dalfopristin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Patients with serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium (VREF) bacteremia.
- Complicated skin and skin structure infections caused by Staphylococcus aureus (MSSA) or Streptococcus pyogenes.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Endocarditis (generally not recommended due to poorer clearance of bacteremia)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: January 27, 2016
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Quinupristin + Dalfopristin
ID - 540467
A1 - Bartlett,John,M.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2016/01/27/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540467/all/Quinupristin_+_Dalfopristin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -